Mersana Therapeutics Inc (Mersana) is a clinical-stage biopharmaceutical company that develops novel antibody-drug conjugates (ADCs). The company develops drugs using Dolasynthen and Immunosynthen platforms. Its pipeline products include XMT-1660, a B7-H4-targeting multiple solid tumors; XMT-2056, a Novel HER2 Epitope that treats multiple solid tumors, XMT-2068 and XMT-2175. Mersana's products treat multiple cancer indications including breast, gastric, colorectal and non-small cell lung cancers. The company works in collaboration with Johnson & Johnson and Merck KGaA. Mersana is headquartered in Cambridge, Massachusetts, the US.
Mersana Therapeutics Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
XMT-1660: Multiple Solid Tumors |
XMT-2056: Multiple Solid Tumors |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Mersana Therapeutics Inc | Pfizer Inc | AbbVie Inc | AstraZeneca Plc | Takeda Pharmaceutical Co Ltd |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | United States of America | United Kingdom | Japan |
City | Cambridge | New York | North Chicago | Cambridge | Chuo-Ku |
State/Province | Massachusetts | New York | Illinois | England | Tokyo |
No. of Employees | 123 | 88,000 | 50,000 | 89,900 | 49,095 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
David Mott | Chairman | Executive Board | 2012 | 58 |
Martin Huber, M.D. | Chief Executive Officer; President; Director | Executive Board | 2023 | 64 |
Brian DeSchuytner | Chief Financial Officer; Senior Vice President; Chief Operating Officer | Senior Management | 2023 | - |
Ashish Mandelia | Chief Accounting Officer; Vice President | Senior Management | 2023 | - |
Alejandra Carvajal | Chief Legal Officer; Senior Vice President | Senior Management | 2021 | 50 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward